Industries > Pharma > Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2021-2031

Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2021-2031

Forecasts by Product (Lucentis, Eylea, Avastin, Visudyne, Others), by Indication (AMD, Diabetic, Macular, Edema, Diabetic, Retinopathy, Retinal Vein, Occlusion, Others), by End-User (Hospital Pharmacy, Retail, Pharmacy, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios

PUBLISHED: 11 February 2021
PAGES: 445
PRODUCT CODE: PHA1039
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA1039 Categories: , Tag:

The global AMD and other retinal disease drugs market accounted for US$xx billion in 2020 and is expected to grow at a CAGR of xx% during the forecast period to reach US$xx billion by 2031. Growing investment in drug R&D by pharmaceutical and biopharmaceutical companies, rising prevalence of retinal diseases, mounting demand for biologics & biosimilars, and developing healthcare infrastructure in emerging economies are some of the major factors that propel the market growth.

Age-related macular degeneration accounts for 8.7% of all blindness worldwide and is the most common cause of blindness in developed countries particularly in people older than 60 years. The prevalence of AMD is likely to increase as a consequence of exponential population ageing.

There have been significant advances in the management of wet age-related macular degeneration with the introduction of anti-angiogenesis therapy, and patients now have effective treatment options that can prevent blindness and, in many cases, restore vision. However, these treatments are expensive and not available to all patients in many countries. The report explains that growth in the market will be driven by the entry of longer-acting anti-angiogenic therapies and the launch of products for dry AMD and geographic atrophy (GA), which are two forms of advanced disease for which there are no approved therapies. Thus, understanding the burden, population impact and treatments options is essential to develop strategies for adequate health care planning and delivery, which require both precise and modern market estimates.

How this report will benefit you
The report provides a thoughtful understanding into the global age-related macular degeneration market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, PEST analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the macular degeneration industry in any manner.

As the coronavirus disease (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.

To access the data contained in this document please email contactus@visiongain.com

In this brand-new 445-page report you will receive 279 charts– all unavailable elsewhere.

The 445-page Visiongain report provides clear detailed insight into the macular degeneration market. Discover the key trends and development in the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

CTA

Report Scope

• Global macular degeneration and other retinal diseases drug market forecasts from 2021-2031

• This report also breaks down the revenue forecast to 2031 for the global macular degeneration and other retinal diseases drug market by indication, type, product and distribution channel:

• By Indication
– Diabetic Macular Edema
– Diabetic Retinopathy
– Retinal Vein Occlusion
– Others

• By Type
– Wet AMD
– Dry AMD
– Geographic Atrophy

• By Product
– Lucentis
– Eylea
– Avastin
– Visudyne
– Others

• By Distribution Channel
– Hospital Pharmacy
– Retail Pharmacy
– Others

This report discusses the market trends and developments of each submarket.

Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2021-2031
Need industry data? Please contact us today.

• Our study discusses the selected leading companies that are the major players in the macular degeneration (AMD) and other retinal diseases drugs market:
– Novartis AG
– F. Hoffmann-La Roche, Ltd.
– GlaxoSmithKline Pharmaceuticals Ltd.
– Bayer AG
– Pfizer Inc.
– Regeneron Pharmaceuticals
– Bausch & Lomb Incorporated
– Apellis Pharmaceuticals
– Santen Pharmaceuticals
– Alimera Sciences
– AbbVie Inc.
– IVERIC bio, Inc. (Formerly Ophthotech)
– Graybug Vision, Inc.
– Kubota Vision Inc.

Visiongain’s study is intended for anyone requiring commercial analyses for the global macular degeneration (AMD) and other retinal diseases drugs market. You find data, trends and predictions.

To access the data contained in this document please email contactus@visiongain.com

Buy our report today Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2021-2031: Forecasts by Product (Lucentis, Eylea, Avastin, Visudyne, Others), by Indication (AMD, Diabetic, Macular, Edema, Diabetic, Retinopathy, Retinal Vein, Occlusion, Others), by End-User (Hospital Pharmacy, Retail, Pharmacy, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2021-2031


Download sample pages

Complete the form below to download your free sample pages for Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2021-2031


Latest Pharma news

Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031

We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

29 July 2021

READ

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

READ

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

READ

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

READ

Categories